PCI Biotech Holding ASA (0JGL) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to PCI Biotech's second half-year 2023 presentation. My name is Ronny Skugudal, and I am CEO and CFO in the company. With me today is Morten Lur, responsible for business development and project manager for the bioprocess project. Please take a look at our important notice and disclaimer. It will be possible to send in questions via the webcast console, so we will try to answer those questions at the end of the presentation. So I encourage you who have an intention to send in questions to start early with that, so that we are sure to have them in hand when we get that far. The agenda today contains a more comprehensive presentation of our bioprocess project, including why and how our technology has a place in the production of viral vectors, as well as the status for 2023 and the outlook for 2024. The first part of the presentation will be about bioprocess. Good morning and welcome to PCI Biotech's second half year 2023 presentation. My name is Ronny Skugudal and I am CEO and CFO in the company. With me today is Morten Lur, responsible for business development and project manager for the bioprocess project. Please pay attention to our important notice and disclaimer. It will be possible to send in questions via the webcast console, so we will try to answer those questions at the end of the presentation. So I encourage you who have an intention to send in questions to start early with that, so that we are sure to have them in hand when we get that far. The agenda today contains a more comprehensive presentation of our bioprocess project, including why and how our technology has a place in the production of viral vectors, as well as the status for 2023 and the outlook for 2024. And the first part of the presentation will be taken by Morten abo...